Personnel Information

写真a

NAGATA Masashi


Job title

Associate Professor

Mail Address

mna-mpha@tmd.ac.jp

Research Areas, Keywords

Pharmacokinetics, Pharmacodynamics
To the head of this page.▲

Graduating School 【 display / non-display 】

  • Tokyo University of Science, Faculty of Pharmaceutical Science, 1997.03, Graduated

To the head of this page.▲

Graduate School 【 display / non-display 】

  • Tokyo University of Science, Graduate School, Division of Pharmaceutical Sciences, Master's Course, 1999.03, Completed

  • Tokyo Medical and Dental University, Doctor's Course, 2003.03, Completed

To the head of this page.▲

Degree 【 display / non-display 】

  • Ph.D., Tokyo Medical and Dental University

To the head of this page.▲

Campus Career 【 display / non-display 】

  • 2003.04
    -
    2005.03
    Tokyo Medical and Dental University， (Old Organization)Medical Hospital， Central Clinical Facilities， Pharmacy， Pharmacist
  • 2011.04
    -
    2017.03
    Tokyo Medical and Dental University， (Old Organization)Medical Hospital， Central Clinical Facilities， Pharmacy， Associate Professor
  • 2017.04
    -
    2018.03
    Tokyo Medical and Dental University， (Old Organization)Medical Hospital， Central Clinical Facilities， Pharmacy， Associate Professor
  • 2018.04
    -
    2021.09
    Tokyo Medical and Dental University， (Old Organization)Medical Hospital， Central Clinical Facilities， Pharmacy， Associate Professor
  • 2021.10
    -
    2023.04
    Tokyo Medical and Dental University， Tokyo Medical and Dental University， Division of Integrated Facilities， Pharmacy， Associate Professor
  • 2023.05
    -
    Now
    Tokyo Medical and Dental University， Tokyo Medical and Dental University， Division of Integrated Facilities， Pharmacy， Associate Professor

▼display all

To the head of this page.▲

External Career 【 display / non-display 】

  • 2005.04
    -
    2009.03
    , Junior Associate Professor
  • 2009.04
    -
    2011.04
    , Senior Staff
To the head of this page.▲

Academic Society Affiliations 【 display / non-display 】

  • American Association of Pharmaceutical Sciences

  • International Society for the Study of Xenobiotics

To the head of this page.▲

Research Areas 【 display / non-display 】

  • Clinical pharmacy

To the head of this page.▲

Qualification Acquired 【 display / non-display 】

  • Pharmacist

To the head of this page.▲
 

Published Papers & Misc 【 display / non-display 】

  1. Noda T, Mizuno S, Mogushi K, Hase T, Iida Y, Takeuchi K, Ishiwata Y, Nagata M. Development of a predictive model for nephrotoxicity during tacrolimus treatment using machine learning methods. British journal of clinical pharmacology. 2024.03; 90 (3): 675-683. ( PubMed, DOI )

  2. Yokoyama K, Yakuo T, Mamada M, Nagata M. Olanzapine Overdose in a Two-Year-Old Girl Resulting in Both High Serum and Plasma Levels. Cureus. 2023.08; 15 (8): e43002. ( PubMed, DOI )

  3. Kaneko S, Asahina Y, Nakagawa M, Murakawa M, Miyazaki Y, Asakage T, Fukuda S, Namiki T, Kano Y, Nagata M, Tsuchiya J, Miyoshi M, Kitahata-Kawai F, Nitta S, Itsui Y, Kakinuma S, Okamoto R. Factors associated with liver injury and prognosis in advanced cancer patients treated with immune checkpoint inhibitors. Hepatology research : the official journal of the Japan Society of Hepatology. 2023.01; 53 (5): 450-459. ( PubMed, DOI )

  4. Xue B, Ishiwata Y, Kawano Y, Takahashi H, Negishi K, Aoyama T, Nagata M. Paliperidone-Induced Acute Hyperglycemia Is Caused by Adrenaline Secretion via the Activation of Hypothalamic AMP-Activated Protein Kinase. Biological & pharmaceutical bulletin. 2022.11; 45 (11): 1669-1677. ( PubMed, DOI )

  5. Takagi M, Ogawa C, Iehara T, Aoki-Nogami Y, Ishibashi E, Imai M, Kimura T, Nagata M, Yasuhara M, Masutani M, Yoshimura K, Tomizawa D, Ogawa A, Yonemori K, Morishita A, Miyamoto S, Takita J, Kihara T, Nobori K, Hasebe K, Miya F, Ikeda S, Shioda Y, Matsumoto K, Fujimura J, Mizutani S, Morio T, Hosoi H, Koike R. First phase 1 clinical study of olaparib in pediatric patients with refractory solid tumors. Cancer. 2022.05; 128 (15): 2949-2957. ( PubMed, DOI )

  6. Kawano Y, Obana M, Nagata M, Mano Y, Katsuyama M, Yamamoto Y, Maeda-Minami A, Negishi K, Takagi M, Shimada S, Aoyama T. The antiplatelet effect of mirtazapine is mediated by co-blocking 5-HT2A and α2-adrenergic receptors on platelets: An in vitro human plasma-based study. European journal of pharmacology. 2022.02; 917 174640. ( PubMed, DOI )

  7. Kawasumi K, Kawano Y, Kujirai A, Mano Y, Matsui R, Maeda-Minami A, Yamamoto Y, Negishi K, Shimada S, Yamaguchi M, Nagata M, Aoyama T. Risk Factors Associated With Unplanned Acute Care in Outpatient Chemotherapy With Oral Anticancer Drugs as Monotherapy or Combination Therapy With Injectable Anticancer Drugs. Anticancer research. 2021.11; 41 (11): 5827-5834. ( PubMed, DOI )

  8. Ishiwata Y, Nagata M, Kiuchi S, Ippongi C, Takeda H, Takahashi H. Intravenous Infusion of Fentanyl Has No Effect on Blood Concentration of Tacrolimus In Patients Receiving Hematopoietic Stem Cell Transplantation. Therapeutic drug monitoring. 2021.10; 43 (5): 688-691. ( PubMed, DOI )

  9. Enomoto A, Mano Y, Kawano Y, Nishikawa T, Aoyama T, Sasaki Y, Nagata M, Takahashi H. Comparison of the Safety and Effectiveness of Four Direct Oral Anticoagulants in Japanese Patients with Nonvalvular Atrial Fibrillation Using Real-World Data. Biological & pharmaceutical bulletin. 2021.09; 44 (9): 1294-1302. ( PubMed, DOI )

  10. Kawano Y, Nagata M, Nakamura S, Akagi Y, Suzuki T, Tsukada E, Hoshiko M, Kujirai A, Nakamatsu S, Nishikawa T, Enomoto A, Negishi K, Shimada S, Aoyama T, Mano Y. Comprehensive Exploration of Medications That Affect the Bleeding Risk of Oral Anticoagulant Users. Biological & pharmaceutical bulletin. 2021.05; 44 (5): 611-619. ( PubMed, DOI )

  11. Asada M, Nagata M, Mizuno T, Uchida T, Takahashi H, Makita K, Arai H, Kijima S, Echizen H, Yasuhara M. Population pharmacokinetics of cefazolin before, during and after cardiopulmonary bypass in adult patients undergoing cardiac surgery. European journal of clinical pharmacology. 2021.04; 77 (5): 735-745. ( PubMed, DOI )

  12. Kawano Y, Katsuyama M, Nagata M, Obana M, Nakamatsu S, Mori A, Sakamoto N, Mano Y, Negishi K, Shimada S, Aoyama T. Antiplatelet Effect of Mirtazapine via Co-blocking of the 5-HT2A and α2-Adrenergic Receptors on Platelets. Biological & pharmaceutical bulletin. 2021.02; 44 (2): 238-244. ( PubMed, DOI )

  13. Yanagie H, Fujino T, Yanagawa M, Terao T, Imagawa T, Fujihara M, Morishita Y, Mizumachi R, Murata Y, Dewi N, Ono Y, Ikushima I, Seguchi K, Nagata M, Nonaka Y, Furuya Y, Hisa T, Nagasaki T, Arimori K, Nakashima T, Sugihara T, Kakimi K, Ono M, Nakajima J, Eriguchi M, Higashi S, Takahashi H. Tumor Growth Suppression With Novel Intra-arterial Chemotherapy Using Epirubicin-entrapped Water-in-oil-in-water Emulsion In Vivo. In vivo. 2021.01; 35 (1): 239-248. ( PubMed, DOI )

  14. Suzuki S, Naito S, Numasawa Y, Asada M, Shoji N, Zeniya M, Takahashi D, Sato H, Iimori S, Nomura N, Sohara E, Okado T, Ishiwata Y, Nagata M, Rai T, Yokota T, Uchida S. Encephalopathy Induced by High Plasma and Cerebrospinal Fluid Ceftriaxone Concentrations in a Hemodialysis Patient. Internal medicine (Tokyo, Japan). 2019.02; ( PubMed, DOI )

  15. Takagi M, Ogawa C, Aoki-Nogami Y, Iehara T, Ishibashi E, Imai M, Kihara T, Nobori K, Hasebe K, Mizutani S, Kimura T, Nagata M, Yasuhara M, Yoshimura K, Yorozu P, Hosoi H, Koike R. Phase I clinical study of oral olaparib in pediatric patients with refractory solid tumors: study protocol. BMC pediatrics. 2019.01; 19 (1): 31. ( PubMed, DOI )

  16. Asada M, Nagata M, Mizuno T, Uchida T, Kurashima N, Takahashi H, Makita K, Arai H, Echizen H, Yasuhara M. Effects of cardiopulmonary bypass on the disposition of cefazolin in patients undergoing cardiothoracic surgery. Pharmacology research & perspectives. 2018.12; 6 (6): e00440. ( PubMed, DOI )

  17. Masashi Nagata, Yuri Kimura, Yasuyoshi Ishiwata, Hiromitsu Takahashi, Masato Yasuhara. Clozapine-Induced Acute Hyperglycemia Is Accompanied with Elevated Serum Concentrations of Adrenaline and Glucagon in Rats. Biol. Pharm. Bull.. 2018.08; 41 (8): 1286-1290. ( PubMed, DOI )

  18. Yasuyoshi Ishiwata, Masashi Nagata, Kohta Tsuge, Hiromitsu Takahashi, Sayo Suzuki, Kohsuke Imai, Masatoshi Takagi, Hirokazu Kanegane, Tomohiro Morio, Masato Yasuhara. Population Pharmacokinetics of Intravenous Busulfan in Japanese Pediatric Patients With Primary Immunodeficiency Diseases. J Clin Pharmacol. 2018.03; 58 (3): 327-331. ( PubMed, DOI )

  19. Yasuyoshi Ishiwata, Masashi Nagata, Takafumi Arai, Misato Makiishi, Maho Yoshikawa, Hiromitsu Takahashi, Hitoshi Kohsaka, Masato Yasuhara. Effects of Miconazole Oral Gel on Blood Concentrations of Tacrolimus and Cyclosporine: A Retrospective Observational Study. Ther Drug Monit. 2016.12; 38 (6): 717-721. ( PubMed, DOI )

  20. Masashi Nagata, Mayumi Nakajima, Yasuyoshi Ishiwata, Yutaka Takahashi, Hiromitsu Takahashi, Kenichi Negishi, Masato Yasuhara. Mechanism Underlying Induction of Hyperglycemia in Rats by Single Administration of Olanzapine. Biol. Pharm. Bull.. 2016.05; 39 (5): 754-761. ( PubMed, DOI )

  21. Masashi Nagata, Yasuyoshi Ishiwata, Yutaka Takahashi, Hiromitsu Takahashi, Kazutaka Saito, Yasuhisa Fujii, Kazunori Kihara, Masato Yasuhara. Pharmacokinetic-pharmacodynamic analysis of sunitinib-induced thrombocytopenia in Japanese patients with renal cell carcinoma. Biol. Pharm. Bull.. 2015.03; 38 (3): 402-410. ( PubMed, DOI )

  22. 徳永 仁, 松尾 徳子, 高村 徳人, 杉本 龍星, 岡崎 愛, 永井 和正, 青木 傳, 緒方 賢次, 瀬戸口 奈央, 吉田 裕樹, 永田 将司, 岸本 修一, 福島 昭二, 池田 理, 西尾 豊隆, 川井 恵一, 有森 和彦. 蛋白結合阻害を利用したcisplatin肝動注療法に関する研究　ラットにおけるL-cysteine併用時におけるcisplatinの体内動態と抗腫瘍効果 九州保健福祉大学研究紀要. 2014.03; (15): 91-97. ( ichushi )

  23. Ishiwata Y, Takahashi Y, Nagata M, Yasuhara M. Effects of moxifloxacin on serum glucose concentrations in rats. Biol Pharm Bull. 2013; 36 (4): 686-690. ( PubMed )

  24. Arino T, Karakawa S, Ishiwata Y, Nagata M, Yasuhara M. Effect of cimetidine on pentamidine induced hyperglycemia in rats. Eur J Pharmacol. 2012.10; 693 (1-3): 72-79. ( PubMed, DOI )

  25. Kawano Y, Nagata M, Kohno T, Ichimiya A, Iwakiri T, Okumura M, Arimori K. Caffeine increases the antitumor effect of Cisplatin in human hepatocellular carcinoma cells. Biol Pharm Bull. 2012; 35 (3): 400-407. ( PubMed )

  26. Nagata M, Hidaka Y, Hatakeyama K, Kawano Y, Iwakiri T, Okumura M, Arimori K. Hepatic fibrosis does not affect the pharmacokinetics of 5-fluorouracil in rats. Biopharm Drug Dispos. 2011.03; 32 (2): 126-130. ( PubMed, DOI )

  27. Nagata M, Hidaka Y, Hidaka M, Kawano Y, Iwakiri T, Okumura M, Arimori K. Effect of acute hepatic failure on the hepatic first-pass effect of 5-fluorouracil in rats. J Pharm Pharmacol. 2010.05; 62 (5): 598-603. ( PubMed, DOI )

  28. Tokunaga J., Matsuo Y., Takamura N., Ogata K., Yoshida H., Nagata M., Kishimoto S., Fukushima S., Ikeda O., Nishio T., Kawai K., Arimori K.. Inhibition of cicplatin protein binding: a possible therapeutic advantage. J. Appl. Ther. Res.. 2010; 7 (4): 127-132.

  29. Nagata M, Matsuo Y, Hidaka M, Kawano Y, Okumura M, Tokunaga J, Takamura N, Arimori K. Effect of acute hepatic failure on epirubicin pharmacokinetics after intrahepatic arterial injection in rats. Biol Pharm Bull. 2008.03; 31 (3): 493-496. ( PubMed )

  30. Iwakiri T, Okumura M, Matsunaga N, Ichihara E, Shiotsuki S, Nagata M, Kumagai Y, Kai H, Arimori K. Hepatocyte growth factor increases uptake of estradiol 17beta-D-glucuronide and Oatp1 protein level in rat hepatocytes. Eur J Pharmacol. 2008.02; 580 (1-2): 19-26. ( PubMed, DOI )

  31. Hidaka M, Nagata M, Kawano Y, Sekiya H, Kai H, Yamasaki K, Okumura M, Arimori K. Inhibitory effects of fruit juices on cytochrome P450 2C9 activity in vitro. Biosci Biotechnol Biochem. 2008.02; 72 (2): 406-411. ( PubMed )

  32. Nagata M, Hidaka M, Sekiya H, Kawano Y, Yamasaki K, Okumura M, Arimori K. Effects of pomegranate juice on human cytochrome P450 2C9 and tolbutamide pharmacokinetics in rats. Drug Metab Dispos. 2007.02; 35 (2): 302-305. ( PubMed, DOI )

  33. Ishiwata Y, Nagata M, Yasuhara M. Effect of isoniazid on the pharmacodynamics of cefazolin-induced seizures in rats. Drug Metab Pharmacokinet. 2005.04; 20 (2): 117-120. ( PubMed )

  34. Nagata M, Fujichika T, Yasuhara M. Effect of experimental renal failure and hypotonic hyponatremia on the pharmacodynamics of cefazolin-induced seizures in rats. Pharm Res. 2003.06; 20 (6): 937-942. ( PubMed )

  35. Nagata M, Yasuhara M. Effect of experimental renal failure on the pharmacodynamics of cefoselis-induced seizures in rats. Biol Pharm Bull. 2001.09; 24 (9): 1049-1052. ( PubMed )

▼display all

To the head of this page.▲

Conference Activities & Talks 【 display / non-display 】

  1. Nagata M.. Challenge of predicting drug and side effects using pharmacometrics and machine learning models. DUPHAT2024 2024.01.11

  2. Noda T., Mizuno S., Hase T., Mogushi K., Iida Y., Ishiwata Y., Nagata M.. Using machine learning algorithm to predict the occurrence of nephrotoxicity with tacrolimus. 81st FIP World Congress of Pharmacy and Pharmaceutical Sciences 2023.09.27

  3. Kawano Y., Kawasumi K., Mano Y., Matsui R., Maeda-Minami A., Yamamoto Y., Negishi K., Shimada S., Nagata M., Aoyama T.. Risk factors associated with unplanned acute care in outpatient chemotherapy with oral anticancer drugs as monotherapy or combination therapy with injectable anticancer drugs. 81st FIP World Congress of Pharmacy and Pharmaceutical Sciences 2023.09.26

  4. Masatoshi Takagi, Chitose Ogawa, Tomoko Iehara, Yuki Aoki-Nogami, Eri Isibashi, Minoru Imai, Toshimi Kimura, Masashi Nagata, Masato Yasuhara, Mitsuko Masutani, Kenichi Yoshimura, Daisuke Tomizawa, Atsushi Ogawa, Kan Yonemori, Tetsuro Kihara, Kiyoshi Nobori, Kazuhisa Hasebe, Shuki Mizutani, Tomohiro Morio, Hajime Hosoi, Ryuji Koike. First In Children Phase I Clinical Study Of Oral Olaparib In Pediatric Patients With Refractory Solid Tumors. SIOP2021 2021.10.24 Honolulu（Web）

  5. Yasuhara M., Asada M., Nagata M., Mizuno T., Uchida T., Takahashi H., Makita K., Arai H., Echizen H.. Population pharmacokinetics of cefazoline before, during and after cardiopulmonary bypass in Japanese patients undergoing cardiothoracic surgery. 2019 AAPS PharmSci 360 2019.11

  6. Kawano Y., Nagata M., Arimori K., Kohno T., Ichimiya A., Uehara K., Aoyama T.. Caffeine increases cisplatin-induced apoptosis via inhibition of Akt pathway and ATM-mediated cell cycle checkpoint pathway in HCC cell lines. 2017 AAPS Annual Meeting and Exposition 2017.11.12 San Diego

  7. Nagata M., Kimura Y., Ishiwata Y., Takahashi H., Yasuhara M.. Epinephrine is involved in clozapine-induced acute hyperglycemia. 2017 AAPS Annual Meeting and Exposition 2017.11.12 San Diego

  8. Odaka M., Nagata M., Mizuno T., Uchida T., Takahashi H., Makita K., Arai H., Echizen H., Yasuhara M.. Effect of cardiopuomonary bypass surgery on unbound fraction of cefazolin in plasma. ASCPT 2017 Annual Meeting 2017.03.17 Washington, DC

  9. Ishiwata Y., Nagata M., Arai T., Makiishi M., Yoshikawa M., Takahashi H., Kohsaka H., Yasuhara M.. Drug-drug interaction of miconazole oral gel with tacrolimus and cyclosporine after oral administration. 2016 AAPS Annual Meeting and Exposition 2016.11.13 Denver

  10. Arimori K., Kawano Y., Nagata M., Kohno T., Ichimiya A., Toyama T., Iwakiri T., Okumura M.. Effect of caffeine on the antitumor effect of cisplatin in human hepatocellular carcinoma cells. 76th FIP’s World Congress of Pharmacy and Pharmaceutical Sciences 2016 2016.08.28 Buenos Aires

  11. Nagata M., Nakajima M., Ishiwata Y., Takahashi Y., Takahashi H., Yasuhara M.. Pharmacokinetic-pharmacodynamic modeling of olanzapine-induced acute hyperglycemia in rats. 11th International ISSX Meeting 2016.06.12 Busan

  12. Yasuhara M., Nagata M., Nakajima M, Ishiwata Y., Takahashi H.. Hyperglycemia induced by a single dose of olanzapine in rats. 2015 AAPS Annual Meeting and Exposition 2015.11.12 Orlando

  13. Masashi Nagata, Yasuyoshi Ishiwata, Masato Yasuhara, Kazutaka Saito, Yasuhisa Fujii, Kazunori Kihara. PK-PD modeling of sunitinib-induced thrombocytopenia in patients with renal cell carcinoma.. 2014 AAPS Annual Meeting and Exposition 2014.11.02 San Diego

  14. Shoichi Kojima, Ryosuke Isozaki, Yasuyoshi Ishiwata, Masashi Nagata, Masato Yasuhara, Fusao Kaiho. Effect of phenytoin on busulfan-induced seizures in rats. 日本薬物動態学会第28年会 2013.10.09 東京

  15. Nagata M., Isozaki R., Ishiwata Y., Yasuhara M.. Development of an animal model to investigate the pharmacodynamics of busulfan-induced myoclonus.. 2012 AAPS Annual Meeting and Exposition 2012.10.14 Chicago

  16. Seiji Karakawa, Toru Arino, Yasuyoshi Ishiwata, Masashi Nagata, Masato Yasuhara. Effect of Pentamidine on Serum Glucose Concentration in Rats. 第5回次世代を担う若手医療薬科学シンポジウム 2011.11.26 名古屋

  17. Yanagie H., Morishita Y., Nishimura R., Kakimi K., Sugiyama H., Takamoto S., Higashi S., Ikushima I., Arimori K., Nagata M., Nagasaki T., Imagawa T., Nakashima T., Terao T., Eriguchi M.. Development of epirubicin entrapped WOW emulsion by double emulfication technique to arterial-injection-chemotherapy for hepatocellular carcinoma.. AACR 100th Annual Meeting 2009 2009.04.18 Denver

  18. Hidaka M., Nagata M., Arimori K. Pharmacokinetic interactions of drugs and fruit juices with carbamazepine in rat.. Enrlich II-2nd World Conference on Magic Bullets 2008.10.03 Nurnberg

  19. Tokunaga J., Takamura N., Furuya Y., Motoya T., Hirai M., Nagata M., Kawachi A., Suzuki A., Matsuoka T.. Approach on clinical pharmacy training Ⅲ in Kyushu university of health and welfare (1): a practice of the bed side training and its evaluation by students.. 21st FAPA Congress 2006.11.18 Yokohama

  20. Yasuhara M., Fujichika T., Nagata M.. Pharmacodynamics of cefazolin-induced seizures in rats with experimental renal failure.. 2002 AAPS Annual Meeting and Exposition 2002.11.08 Toronto

  21. Nagata M., Inotsume N., Yasuhara M.. Effect of experimental renal failure on the pharmacodynamics of cefoselis-induced seizures in rats.. Ⅶ World Conference on Clinical Pharmacology and Therapeutics 2000.07.15 Florence

▼display all

To the head of this page.▲

Others 【 display / non-display 】

  • Mechanisms and Risk Factors for Drug-Induced Dysglycemia，2015.10

    AAPS Blog,2015/10/27
    http://aapsblog.aaps.org/2015/10/27/mechanisms-and-risk-factors-for-drug-induced-dysglycemia/

To the head of this page.▲